---
document_datetime: 2024-09-09 12:13:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_en.pdf
document_name: nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6959535
conversion_datetime: 2025-12-27 15:44:12.331858
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/20/1485/001 | NYXTHRACIS        | 100 mg/ml  | Concentrate for solution for infusion | Intravenous use longer    | Vial (glass)          | 6 ml authorised           | 1 vial      |